What Is the Palantir NHS Contract Controversy?

Not affiliated with Palantir Technologies Inc. This is an active, unresolved UK political story as of mid-2026 — we've laid out what's documented on each side. Sources are cited throughout.

Palantir holds a contract, worth up to £330 million over seven years, to build and run the NHS Federated Data Platform (FDP) in England — a system meant to join up the NHS's historically fragmented patient data. The relationship has generated sustained controversy since before the contract was even awarded, centering on patient consent, data access, contract transparency, and cost. As of mid-2026, a contractual break clause due in spring 2027 has made the second half of 2026 a genuine decision point for whether the UK government keeps or ends the arrangement.

How the relationship started

Palantir's NHS involvement began in March 2020, when it was brought in — without a competitive tender, under emergency COVID-19 procurement rules — to help build the NHS COVID-19 Data Store, initially for a nominal £1 fee before being extended in a £23 million renewal. The Federated Data Platform itself was awarded through a competitive process in November 2023 to a Palantir-led consortium, though critics have argued Palantir's incumbent position from the COVID work gave it a structural advantage — a dynamic sometimes called vendor lock-in.

The core patient-consent dispute

The most persistent controversy is that patients in England cannot opt out of having their data processed by the FDP specifically. In June 2026, UK health minister Preet Kaur Gill confirmed to the House of Commons that the National Data Opt-Out doesn't currently apply to FDP products, because the relevant data use is classified as "direct care." Individual NHS trusts, as institutions, can decline to adopt the platform — and as of that same period, only one of England's 42 integrated care boards (Greater Manchester) had refused to sign up. Separately, lawyers have told NHS England that key aspects of the FDP's legal basis are unclear, and campaign groups (including the Good Law Project and Foxglove) have pursued legal challenges arguing the platform lacks proper legal grounding under existing NHS data-sharing rules.

Who is raising concerns

• The British Medical Association has criticized the arrangement and instructed doctors to limit their engagement with the platform.
• A cross-party committee of MPs (the Science, Innovation and Technology Committee) has formally urged the government to use the 2027 break clause to end the contract.
• Medact, a health-justice charity, released a briefing backed by doctors, lawyers, patients, and rights groups (including the Good Law Project, Privacy International, Corporate Watch, and Amnesty International) warning that Palantir's software could enable data-driven abuses of power similar to what's been documented in its U.S. ICE work.
• Parliamentary debate has also raised reports that some NHS staff were warned they could face consequences for criticizing the contract, and that some organizations felt pressured to adopt the platform — claims attributed to reporting by Novara Media and the Financial Times.
• Cost scrutiny: as of late 2026, the platform's projected whole-life cost has been revised upward to roughly £1.1 billion while forecast benefits have been revised down to around £808 million, according to figures reported via the Financial Times and the National Infrastructure and Service Transformation Authority.

What NHS England and Palantir say

NHS England states that Palantir operates strictly as a data "processor" under UK data protection law — meaning it can only use NHS data as directed by NHS staff, not independently. NHS England has also stated that all data is stored and processed exclusively within the UK, with a contractual requirement that Palantir personnel or contractors based outside the UK cannot access personal data held in the system. On the broader opt-out question, NHS England has said a mass opt-out would undermine the quality of the shared datasets used for research and public health planning. Palantir has defended the platform's data-protection rules as adequate to protect patients — a claim that campaign groups and some parliamentarians continue to dispute directly.

What's still unresolved

The UK government has signaled it's evaluating whether to exit the contract early via the spring 2027 break clause, with a decision expected before then. Ongoing legal challenges over the platform's legal basis and contract transparency (including redactions in the published contract terms) remain active as of this writing, and the outcome will likely shape how the story develops from here.